Cargando…

Initiation of antidepressant medication in people with type 2 diabetes living in the United Kingdom—A retrospective cohort study

INTRODUCTION: Depression is a common comorbidity in people with type 2 diabetes and it is associated with poorer outcomes. There is limited data on the treatments used for depression in this population. The aim of this study was to explore the rates of initiation of antidepressant prescriptions in p...

Descripción completa

Detalles Bibliográficos
Autores principales: Pal, Kingshuk, Sharma, Manuj, Mukadam, Naaheed M., Petersen, Irene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542279/
https://www.ncbi.nlm.nih.gov/pubmed/35638365
http://dx.doi.org/10.1002/pds.5484
_version_ 1784804114090164224
author Pal, Kingshuk
Sharma, Manuj
Mukadam, Naaheed M.
Petersen, Irene
author_facet Pal, Kingshuk
Sharma, Manuj
Mukadam, Naaheed M.
Petersen, Irene
author_sort Pal, Kingshuk
collection PubMed
description INTRODUCTION: Depression is a common comorbidity in people with type 2 diabetes and it is associated with poorer outcomes. There is limited data on the treatments used for depression in this population. The aim of this study was to explore the rates of initiation of antidepressant prescriptions in people with type 2 diabetes in the UK and identify those most at risk of needing such treatment. RESEARCH DESIGN AND METHODS: This was a retrospective cohort study using data from IQVIA Medical Research Data (IMRD)‐UK data. Data from general practices in IMRD‐UK between January 2008 and December 2017 were used for this study. RESULTS: The overall rates of antidepressant prescribing were stable over the study period. The rate of initiation of antidepressant medication in people with type 2 diabetes was 22.93 per 1000 person years at risk (PYAR) with a 95%CI 22.48 to 23.39 compared to 16.89 per 1000 PYAR (95%CI 16.77 to 17.01) in an age and gender matched cohort. The risk of being prescribed antidepressant medication with age had a U‐shaped distribution with the lowest risk in the 65–69 age group. The peak age for antidepressant initiation in men and women was 40–44, with a rate in men of 32.78 per 1000 PYAR (95% CI 29.57 to 36.34) and a rate in women of 46.80 per 1000 PYAR (95% CI 41.90 to 52.26). People with type 2 diabetes with in the least deprived quintile had an initiation rate of 19.66 per 1000 PYAR (95%CI 18.67 to 20.70) compared to 27.19 per 1000 PYAR (95%CI 25.50 to 28.93) in the most deprived quintile, with a 32% increase in the risk of starting antidepressant medication (95%CI 1.22 to 1.43). CONCLUSIONS: People with type 2 diabetes were 30% more likely to be started on antidepressant medication than people without type 2 diabetes. Women with type 2 diabetes were 35% more likely than men to be prescribed antidepressants and the risks increased with deprivation and in younger or older adults, with the lowest rates in the 65–69 year age band. The rates of antidepressant prescribing were broadly stable over the 10‐year period in this study. The antidepressant medications prescribed changed slightly over time with sertraline becoming more widely used and fewer prescriptions of citalopram.
format Online
Article
Text
id pubmed-9542279
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-95422792022-10-14 Initiation of antidepressant medication in people with type 2 diabetes living in the United Kingdom—A retrospective cohort study Pal, Kingshuk Sharma, Manuj Mukadam, Naaheed M. Petersen, Irene Pharmacoepidemiol Drug Saf Original Articles INTRODUCTION: Depression is a common comorbidity in people with type 2 diabetes and it is associated with poorer outcomes. There is limited data on the treatments used for depression in this population. The aim of this study was to explore the rates of initiation of antidepressant prescriptions in people with type 2 diabetes in the UK and identify those most at risk of needing such treatment. RESEARCH DESIGN AND METHODS: This was a retrospective cohort study using data from IQVIA Medical Research Data (IMRD)‐UK data. Data from general practices in IMRD‐UK between January 2008 and December 2017 were used for this study. RESULTS: The overall rates of antidepressant prescribing were stable over the study period. The rate of initiation of antidepressant medication in people with type 2 diabetes was 22.93 per 1000 person years at risk (PYAR) with a 95%CI 22.48 to 23.39 compared to 16.89 per 1000 PYAR (95%CI 16.77 to 17.01) in an age and gender matched cohort. The risk of being prescribed antidepressant medication with age had a U‐shaped distribution with the lowest risk in the 65–69 age group. The peak age for antidepressant initiation in men and women was 40–44, with a rate in men of 32.78 per 1000 PYAR (95% CI 29.57 to 36.34) and a rate in women of 46.80 per 1000 PYAR (95% CI 41.90 to 52.26). People with type 2 diabetes with in the least deprived quintile had an initiation rate of 19.66 per 1000 PYAR (95%CI 18.67 to 20.70) compared to 27.19 per 1000 PYAR (95%CI 25.50 to 28.93) in the most deprived quintile, with a 32% increase in the risk of starting antidepressant medication (95%CI 1.22 to 1.43). CONCLUSIONS: People with type 2 diabetes were 30% more likely to be started on antidepressant medication than people without type 2 diabetes. Women with type 2 diabetes were 35% more likely than men to be prescribed antidepressants and the risks increased with deprivation and in younger or older adults, with the lowest rates in the 65–69 year age band. The rates of antidepressant prescribing were broadly stable over the 10‐year period in this study. The antidepressant medications prescribed changed slightly over time with sertraline becoming more widely used and fewer prescriptions of citalopram. John Wiley & Sons, Inc. 2022-06-10 2022-08 /pmc/articles/PMC9542279/ /pubmed/35638365 http://dx.doi.org/10.1002/pds.5484 Text en © 2022 The Authors. Pharmacoepidemiology and Drug Safety published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Pal, Kingshuk
Sharma, Manuj
Mukadam, Naaheed M.
Petersen, Irene
Initiation of antidepressant medication in people with type 2 diabetes living in the United Kingdom—A retrospective cohort study
title Initiation of antidepressant medication in people with type 2 diabetes living in the United Kingdom—A retrospective cohort study
title_full Initiation of antidepressant medication in people with type 2 diabetes living in the United Kingdom—A retrospective cohort study
title_fullStr Initiation of antidepressant medication in people with type 2 diabetes living in the United Kingdom—A retrospective cohort study
title_full_unstemmed Initiation of antidepressant medication in people with type 2 diabetes living in the United Kingdom—A retrospective cohort study
title_short Initiation of antidepressant medication in people with type 2 diabetes living in the United Kingdom—A retrospective cohort study
title_sort initiation of antidepressant medication in people with type 2 diabetes living in the united kingdom—a retrospective cohort study
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542279/
https://www.ncbi.nlm.nih.gov/pubmed/35638365
http://dx.doi.org/10.1002/pds.5484
work_keys_str_mv AT palkingshuk initiationofantidepressantmedicationinpeoplewithtype2diabeteslivingintheunitedkingdomaretrospectivecohortstudy
AT sharmamanuj initiationofantidepressantmedicationinpeoplewithtype2diabeteslivingintheunitedkingdomaretrospectivecohortstudy
AT mukadamnaaheedm initiationofantidepressantmedicationinpeoplewithtype2diabeteslivingintheunitedkingdomaretrospectivecohortstudy
AT petersenirene initiationofantidepressantmedicationinpeoplewithtype2diabeteslivingintheunitedkingdomaretrospectivecohortstudy